Protocol of PEACH in Asia study (English version)
November 3rd, 2022 (by the principal investigator, Sochiro Ohara, Japan)

CONFIDENTIAL INFORMATION

PEACH in Asia: PEri-Anesthetic morbidity in CHildren in Asia

A prospective multinational multicenter observational study to investigate epidemiology of severe critical events in pediatric anesthesia in Asia

Protocol ID: PEACH in Asia

Study Protocol

Dated November 3rd, 2022

UMIN Clinical Trials Registry identifier # UMIN000046328 (Already Registered)
https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000052803

Corresponding author:
Soichiro Ohara
Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan
Teikyo University Graduate School of Public Health, Tokyo, Japan
E-mail address: soichoba1975@gmail.com

On behalf of the Asian Society of Paediatric Anaesthesiologists Research Committee

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Protocol of PEACH in Asia study (English version)
November 3rd, 2022 (by the principal investigator, Sochiro Ohara, Japan)

Table of Contents

<table>
<thead>
<tr>
<th>No.</th>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>General Information</td>
<td>3</td>
</tr>
<tr>
<td>1.1</td>
<td>Steering Committee</td>
<td>3</td>
</tr>
<tr>
<td>1.2</td>
<td>Summary of the PEACH in Asia study</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>Introduction and Background Information</td>
<td>5</td>
</tr>
<tr>
<td>2.1</td>
<td>Summary of findings from clinical studies that are related to the PEACH in Asia study</td>
<td>5</td>
</tr>
<tr>
<td>2.2</td>
<td>Compliance of study with the protocol, good clinical practice standards, and the applicable regulatory requirement(s)</td>
<td>7</td>
</tr>
<tr>
<td>3</td>
<td>Trial Objective and Purpose</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>Study Design</td>
<td>9</td>
</tr>
<tr>
<td>4.1</td>
<td>Type/ Design of Study</td>
<td>9</td>
</tr>
<tr>
<td>4.2</td>
<td>Outcome Measures</td>
<td>10</td>
</tr>
<tr>
<td>4.3</td>
<td>Data Collection</td>
<td>10</td>
</tr>
<tr>
<td>4.4</td>
<td>Description of the measures taken to minimize/ avoid bias</td>
<td>14</td>
</tr>
<tr>
<td>4.5</td>
<td>Expected duration of subject participation and description of the sequence and duration of study periods</td>
<td>15</td>
</tr>
<tr>
<td>4.6</td>
<td>“Stopping rules” or “discontinuation criteria” for individual subjects, parts of study and entire study</td>
<td>15</td>
</tr>
<tr>
<td>4.7</td>
<td>Pilot Testing</td>
<td>15</td>
</tr>
<tr>
<td>5</td>
<td>Selection and Withdrawal of Subjects</td>
<td>17</td>
</tr>
<tr>
<td>5.1</td>
<td>Subject Inclusion/ Exclusion Criteria</td>
<td>17</td>
</tr>
<tr>
<td>5.2</td>
<td>Subject Withdrawal Criteria</td>
<td>18</td>
</tr>
<tr>
<td>6</td>
<td>Statistics</td>
<td>19</td>
</tr>
<tr>
<td>6.1</td>
<td>Sample size</td>
<td>19</td>
</tr>
<tr>
<td>6.2</td>
<td>Participating centers</td>
<td>19</td>
</tr>
<tr>
<td>6.3</td>
<td>Method</td>
<td>20</td>
</tr>
<tr>
<td>6.4</td>
<td>The level of significance to be used</td>
<td>20</td>
</tr>
<tr>
<td>6.5</td>
<td>Criteria for the termination of the study</td>
<td>20</td>
</tr>
<tr>
<td>6.6</td>
<td>Procedures for accounting for missing, unused, and spurious data</td>
<td>21</td>
</tr>
<tr>
<td>6.7</td>
<td>The selection of subjects to be included in the analyses</td>
<td>21</td>
</tr>
<tr>
<td>7</td>
<td>Quality Assurance and Quality Control</td>
<td>22</td>
</tr>
<tr>
<td>8</td>
<td>Ethics Description of Ethical Considerations Relating To The Study</td>
<td>23</td>
</tr>
<tr>
<td>9</td>
<td>Data Handling and Record Keeping</td>
<td>24</td>
</tr>
<tr>
<td>10</td>
<td>Publication Policy</td>
<td>26</td>
</tr>
<tr>
<td>11</td>
<td>References</td>
<td>27</td>
</tr>
<tr>
<td>12</td>
<td>Lists of Appendices</td>
<td>29</td>
</tr>
</tbody>
</table>
1. General Information

1.1 Steering Committee

Asian Society of Paediatric Anaesthesiologists Research Committee
(Asian Paediatric Anaesthesia Research group: A-PEAR)

Soichiro Obara (Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan) (principal investigator)
Choon Looi Bong (KK Women’s and Children’s Hospital, Singapore, Singapore) (co-principal investigator)
Zehra Serpil Ustalar Ozgan (Acibadem Altunizade Hospital, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey)
Mahin Seyedhejazi (Tabriz University of Medical Sciences, Tabriz, Iran)
Shemila Abbasi (Aga Khan University, Karachi, Pakistan)
Elsa Varghese (Kasturba Medical College & Hospital, Manipal University, Manipal, India)
Evangeline K Villa (College of Medicine and Philippine General Hospital, University of the Philippines, Manila, the Philippines)
Andi Ade W Ramlan (Dr. Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia)
Ina Ismiarti Binti Shariffuddin (University of Malaya, Kuala Lumpur, Malaysia)
Patcharee Sriswasdi (Siriraj Hospital, Mahidol University, Bangkok, Thailand)
Pheakdey Nhoung (National Pediatric Hospital, Phnom Penh, Cambodia)
Vivian Yuen (Hong Kong Children’s Hospital, Hong Kong, China)
Hyo-Jin Byon (Yonsei University College of Medicine, Seoul, Republic of Korea)

President of Asian Society of Paediatric Anaesthesiologists
Josephine S K Tan (Singapore) (co-principal investigator)

World Federation of Societies of Anesthesiologists, pediatric committee
Norifumi Kuratani (Japan) (co-principal investigator)

Sponsorship
The PEACH in Asia study is sponsored by the Asian Society of Pediatric Anesthesiologists Research group (A-PEAR). The aim of the A-PEAR is to provide an infrastructure for clinical research in the fields of pediatric anesthesia mainly by international collaborative studies.
Protocol of PEACH in Asia study (English version)
November 3rd, 2022 (by the principal investigator, Sochiro Ohara, Japan)

The Steering Committee of this study, PEACH in Asia study, can be contacted via:

E-mail: peachinasia@gmail.com
Webpage: (under construction as of November 3rd, 2022)

Endorsement
The PEACH in Asia study has been endorsed by the following societies/organizations:
- Asian Society of Paediatric Anaesthesiologists (ASPA)

1.2 Summary of the PEACH in Asia study

Despite the introduction of better-structured programs for pediatric anesthesia training and the development of some recommendations for pediatric anesthesia services, the incidence of severe critical events in children is still unknown in Asia. Considering that the major life-threatening complications following general or regional anesthesia are uncommon, it is therefore crucial to consider a large multinational, multicenter trial in order to establish a realistic statistical estimation and identify the risk factors for severe critical events. Thus, this international prospective observational multicenter observational study, Peri-anesthetic morbidity in children in Asia (PEACH in Asia) study, is designed to identify the incidence and potential risk factors of severe critical events in children undergoing anesthesia in Asia, which will work as a powerful road map to develop and implement data-driven pediatric surgery and anesthesia plans in Asia.
2. Introduction and Background Information

2.1 Summary of findings from clinical studies that are related to the PEACH in Asia study

Multiple pediatric studies performed in high-income countries have shown that pediatric anesthesia-related mortality has declined to approximately 1-5 children out of 10,000 who receive anesthetics (0.01-0.05%), despite the methodological variations between the studies [1-7]. While relatively fewer pediatric data has been obtained from developing countries, pediatric anesthesia-related mortality in developing countries seems to be twice or thrice that in developed countries [6,7]. The rates of pediatric anesthesia-related serious adverse events remain around 2-8% in developed countries [6-10]. The recent prospective cohort study Anesthesia Practice in Children Observational Trial (APRICOT) revealed large variability in anesthesia practice across 33 European countries, with a high overall incidence (5.2%) of perioperative severe critical events [11]. Anesthesia-related adverse events occur at similar rates in Asian countries: 4.6% among infants in Thailand [12], 3.3% across all pediatric patients in Singapore [13], and 8.9% among patients aged 15 or less in India [14].

Although Pediatric anesthesia-related cardiac arrest and serious adverse event rates vary depending on locality, three high-risk categories for mortality and morbidity seem to be consistent across the developed and developing countries [6,7]: younger than 1 year of age, American Society Anesthesiologists (ASA) Physical Status (PS) III-V, and emergency surgery. Up to 75% of anesthetic-related cardiac arrests and critical incidents are considered preventable [1-3, 6, 7]. Awareness and comprehension of the common perioperative pediatric life support scenarios will raise the standard of safety and quality in the field [15]. Institutions in the UK and North America have implemented a simulation-based training course (Managing Emergencies in Pediatric Anesthesia: MEPA) to provide experience in managing anesthetic emergencies when treating children [16]; however, it has not been fully determined whether simulation training improves outcomes [16-19].

The Asian Society of Pediatric Anesthesiologists (ASPA) began Pediatric Perioperative Life Support (PPLS) courses in 2014 that have been conducted by experienced pediatric anesthesiologists from multiple Asian countries. We have since provided instructors and training material, held workshops in, and developed the programs and materials of institutions in Asian countries such as the Maldives, Malaysia, Mauritius, Cambodia, Lao PDR, India, Philippines, Sri Lanka, China, Thailand, Turkey, Indonesia, and Nepal (in chronological order). The minute reports of each course have been published, updated, and are available on the ASPA official webpage [20].
Protocol of PEACH in Asia study (English version)

November 3rd, 2022 (by the principal investigator, Sochiro Ohara, Japan)

As is the case of other international scientific meetings, conferences, and educational courses, almost all the ASPA PPLS courses have been obliged to cancel due to the ongoing COVID-19 pandemic. Hence, the current pandemic has required the ASPA to continue such educational endeavors in different “avatars”, just as it has been making impact on anesthesiology training [21-23]. For example, the ASPA launched online educational lectures delivered by our ASPA Educational Committee members in July 2020, which has been continued on a monthly basis as of July 2021 with funding support from the World Federation of Societies of Anesthesiologists (WFSA) [24].

Despite the introduction of better-structured programs for pediatric anesthesia training, there is a dearth of data concerning whether our PPLS courses have helped to attenuate morbidity and mortality in pediatric perioperative care in the countries or regions in Asia. As with other studies that have shown the effect of educational courses on the performance of tasks related to anesthesia, [25,26] the ASPA must examine the impact of our PPLS courses beyond their theoretical contributions to patient safety. Simple metrics such as 24-hour perioperative and anesthesia-related morbidity and mortality rates are essential indicators of access to and safety of pediatric surgery [6,7,27]. Hence, as a next step in international collaborative research, the ASPA will perform a joint clinical research project to examine pediatric perioperative morbidity and mortality rates in Asian countries and regions through the adoption of inclusive definitions and simple data collection. Similar to the European prospective multicenter observational study [11], we will thus propose this prospective observational multicenter cohort study, which is designed to investigate the incidence of serious adverse event rates among neonates and children undergoing anesthesia and reveal regional differences in pediatric anesthesia practices in Asia.

The study aims to include all children from birth to 15 years old scheduled for an elective or urgent diagnostic or surgical procedure under sedation or general anesthesia with or without regional analgesia or under regional anesthesia. This represents the denominator dataset for calculation of the incidence of severe critical events, which is the primary aim of the study. The anesthesiologist in charge will record the occurrence of selected severe critical events during and up to 60 minutes after anesthesia or sedation AND requiring immediate intervention. These severe critical incidents include: laryngospasm, bronchospasm, pulmonary aspiration, drug error, anaphylaxis, cardiovascular instability, neurological damage, peri-anesthetic cardiac arrest and post-anesthetic stridor. The secondary endpoint is represented by the risk factors and the consequences for the occurrence of these severe critical events including in-hospital mortality established up to 30 days or at discharge. Relevant aspects of the child’s medical and family history will be recorded.

On the basis of the European APRICOT (the rate of severe critical events: mean 5.2% [95% confidence
interval (CI) 5.0-5.5] and considering the occurrence of the severe critical events studied in several Asian countries (all are single-center study: 3.3% in Singapore, 8.9% in India, and so on), we anticipate that a minimum of approximately 7,600 patients would provide a 95% CI of 1.0% for the overall incidence of severe critical events with an acceptable confidence width (assuming that the incidence of severe critical events is 5.2% with 95% CI of 4.7-5.7%). If we were able to recruit more patients as over 30,000, we could anticipate narrower CI such as 0.5%, assuming that the incidence of severe critical events is 5.2% with 95% CI of 5.0-5.5% as the European APRICOT. Thus, we plan to recruit at least 7,600 children over a period of two consecutive weeks including weekends and after-hours across the 15 Asian countries and regions represented at the Asian Society of Pediatric Anesthesiologists Council or part of geographical Asia. The 2-week recruitment period will be chosen by each site commencing on 01 April 2023 (as planned), after a pilot study will be conducted at a few participating institutions to confirm the feasibility of the protocol. The last possible inclusion date will be decided by the Study Steering Committee depending on the recruitment rate. Participating institutions will be provided with data acquisition sheets that enable anonymous standardized recording of all patients' parameters, which will be used by the local institution to fill in the electronic case report form (e-CRF).

Descriptive statistical analysis will be performed for the primary endpoint (occurrence of severe critical events and 95% confidence interval). Univariate and multivariate analysis will be performed to test factors associated with the endpoint. Results of logistic regression will be reported as adjusted odds ratio (OR) with 95% confidence intervals.

2.2 Compliance of study with the protocol, good clinical practice standards, and the applicable regulatory requirement(s)

This study will be conducted in compliance with the protocol approved by the Institutional Review Board (IRB), and according to Good Clinical Practice (GCP) standards. No substantial Amendment to the protocol will be implemented without the prior review and approval of the IRB. This is however highly unlikely as this study is observational. Particular regulatory requirements of specific countries will be followed.
3. Trial Objective and Purpose

The aims of the PEACH in Asia study are:
1. To establish the incidence of severe critical events in children undergoing anesthesia in Asia.
2. To describe the differences in pediatric anesthesia practice throughout Asia.
3. To study the potential impact of this variability on the occurrence of severe critical events (Laryngospasm, Bronchospasm, Pulmonary aspiration, Drug error, Anaphylaxis, Cardiovascular instability, Neurological damage, Peri-anesthetic cardiac arrest and post-anesthetic Stridor).

Unlike in Europe or North America, there is a dearth of data related to morbidity and mortality in pediatric peri-anesthetic care in Asia. Hence, this will be the first implementation study to examine the incidence of severe critical events in children undergoing anesthesia throughout Asia. The obtained data and results will, for sure, work as indices of access to and safety of pediatric surgery in Asia.
4. Study Design

4.1 Type/ Design of Study

Study Type: Observational
Observational Model: Cohort
Time Perspective: Prospective
Official Title: PEACH in Asia: PErI-Anesthetic morbidity in CHildren in Asia – A prospective multinational multicenter observational study to investigate epidemiology of severe critical events in pediatric anesthesia in Asia
(Planned) Study Start Date: 01 April 2023
(Hopeful) Primary Completion Date: 03 March 2024
(Hopeful) Study Completion Date: 30 September 2024

PEACH in Asia study is a prospective, descriptive study and only includes objective data collected as part of routine anesthetic care. As a consequence PEACH in Asia study has to be referred to as an observational trial, where no intervention takes place. Therefore this study is neither double-blind, nor placebo-controlled. Apart from standardized data acquisition no specific procedures are performed. An outline of the trial design is given in the protocol flow chart.

4.2 Outcome Measures

Primary Outcome Measures:

1. Incidence of severe critical events [Time Frame: Children will be followed for the duration of
Protocol of PEACH in Asia study (English version)
November 3rd, 2022 (by the principal investigator, Sochiro Ohara, Japan)

their anesthesia procedure and up to 60 minutes afterwards]

Incidence of the following severe critical events defined as any incident occurring during and up to 60 minutes after anesthesia or sedation (PACU), requiring immediate intervention and that may lead to major disability and/or death:

- Laryngospasm
- Bronchospasm
- Pulmonary aspiration
- Drug error
- Anaphylaxis
- Cardiovascular instability
- Neurological damage
- Peri-anesthetic Cardiac arrest
- Postanesthetic Stridor

Secondary Outcome Measures:

1. **Risk factors for the occurrence of severe critical events [Time Frame: Children will be followed for the duration of their anesthesia procedure and up to 60 minutes afterwards]**

   Assessment of risk factors will be achieved by collecting data on social and demographic data of the patients, family and child's medical history, presence of co-morbidities, details on anesthesia procedure, elective or emergency cases, level of experience of the anesthesiologist, postoperative prescriptions.

2. **Consequences of the critical events: irreversible damage, in-hospital mortality [Time Frame: in-hospital and up to 30 days]**

   Consequences of critical events: no harm, minor sequelae, irreversible damage, in-hospital mortality (up to 30 days or discharge).

4.3 Data Collection

The following data will be collected for each patient:
Protocol of PEACH in Asia study (English version)
November 3rd, 2022 (by the principal investigator, Sochiro Ohara, Japan)

(1) Demographic data
   Age, history of prematurity, gender, weight, ethnicity, ASA physical status classification

(2) Medical history
   Presence of current upper respiratory infection (less than 2 weeks), history of wheezing and/or chronic dry cough at night and/or eczema in the last 12 months, allergy, atopy, fever > 38.5°C in the last 24 hours, family history of smoking.

(3) Medication and/or natural or homeopathic products

(4) Parameters related to the anesthesia team and to the procedure
   Information about the pre-anesthetic consultation, the anesthesia team in charge, the surgical or non-surgical indication, the timing of the procedure (elective, emergency; opening operating room hours or after hours), and whether it is ambulatory or inpatient.
   Definition of emergency procedure: non-elective procedure is performed when the patient’s life or well-being is in direct jeopardy.
   When a procedure is scheduled in advance and does not involve any medical emergency/urgency, it is an elective procedure.

(5) Type of premedication and route of administration, parental presence at induction

(6) Anesthesia management
   Type of monitoring, variables related to the induction (type, sequence, drugs used), maintenance (drugs, use of nitrous oxide or not), any additional regional analgesia (technique, test dose, drugs), airway management (type used, difficulties, use of cuffed tubes, monitoring and technique of removal on awakening), type of ventilation used, fluid management (maintenance, compensation of fluid losses, blood transfusion, coagulation factors) and finally duration of the procedure (defined as wheel-in / wheel-out, as to represent when the patient enters or leaves the operating room or when the anesthesiologist starts looking after the child if a procedure is performed outside the operating room).

(7) Recording of severe adverse events occurring during anesthesia and up to 60 minutes afterwards defined as it follows

The following definitions, mostly based on validated or published studies in the field of pediatric anesthesia will be used in the PEACH in Asia study:
1. Laryngospasm: is defined either as complete airway obstruction associated with rigidity of the abdominal and chest walls and leading to unsuccessful child's ventilation, or glottic closure associated with chest movement but silent unsuccessful child's respiratory efforts and assisted ventilation, unrelieved in both situations with simple jaw thrust and CPAP maneuvers and requiring the administration of medication (propofol, suxamethonium etc.) and/or tracheal intubation.

2. Bronchospasm: is defined as an increased respiratory effort, especially during expiration, and wheeze on auscultation. If the patient is ventilated, bronchospasm may also be considered if a significant increase in peak inspiratory pressure (under volume controlled ventilation) or significant decrease in tidal volume (under pressure controlled ventilation) are observed. In all cases, any episode of airway constriction requiring the administration of a bronchodilator will be recorded.

3. Pulmonary aspiration: is defined as the presence of any non-respiratory secretions (bilious or particulate) in the airway as evidenced by laryngoscopy, suctioning, or bronchoscopy. In a situation where there was suspicion of pulmonary aspiration but no positive aspiration of non-respiratory secretions, new clinical and/or chest X-ray signs consistent with aspiration are accepted as evidence for it (e.g., new wheeze or crackles in the chest after regurgitation or vomiting incident).

4. Drug error: is defined as the administration of a wrong drug, or a wrong dose given by any route, or a wrong site of administration, that has led to either respiratory/cardiac/neurological consequence or to an unplanned admission to the intensive care unit or prolonged hospitalization.

5. Anaphylaxis: is defined by the occurrence of any suspected IgE or non-IgE mediated severe allergic reaction leading to cardiovascular instability and/or severe bronchospasm and requiring immediate resuscitation (fluid resuscitation and epinephrine).

6. Cardiovascular instability: is defined by the occurrence of either one of the following:
   a) cardiac arrhythmia defined as ECG evidence of cardiac rhythm disturbance considered by clinical staff to be severe enough to require treatment (e.g. anti-arrhythmic agents, vasoactive agents, intravenous fluid, etc.). This includes arrhythmias occurring following regional analgesia and requiring intervention. For example: bradycardia requiring atropine,
Protocol of PEACH in Asia study (English version)
November 3rd, 2022 (by the principal investigator, Sochiro Ohara, Japan)

supraventricular tachycardia, atrial or ventricular tachyarrhythmia, torsade de Pointe, etc.
b) hypotension defined as a drop in blood pressure requiring intervention by the anesthesiologist (fluid resuscitation and/or the administration of vasoactive drugs)
c) bleeding resulting in hypotension and necessitating unanticipated and unpredicted blood transfusion
d) cardiovascular instability despite anticipated bleeding and transfusion (e.g.: liver transplant, scoliosis...)

7. Neurological damage: is defined in case of regional anesthesia by the occurrence of nerve injury or spinal cord insult or seizure requiring resuscitation. In case of general anesthesia, any episode of seizure, pressures sore, episodes of loss of vision or new onset of central neurological impairment. This includes peripheral nerve injury following positioning (ulnar nerve, external popliteal nerve) or puncture (median or ulnar nerve).

8. Peri-operative cardiac arrest: is defined as cessation of circulation (e.g. pulseless electric activity, asystole, ventricular fibrillation/tachycardia) requiring open or closed chest compressions, or resulting in death, while the patient is in the care of the anesthetic team. Three advocators, among the local anesthetic team, will determine the anesthetic responsibility for cardiac arrest.

9. Post-operative Stridor: is defined as a severe inspiratory flow limitation with sternal retraction, intrathoracic pressure swing, and potentially cyanosis occurring in the PACU and necessitating the administration of oxygen, intravenous steroids and/or epinephrine (nebulization) or tracheal intubation.

(8) Postoperative data will be collected to gather information about the patient’s transfer and the health providers in charge. In addition to the severe adverse events listed above, it will be recorded whether the child received oxygen.

(9) Parameters related to postoperative analgesia will also be recorded as to the type of analgesia, the drugs used and the route of administration.

(10) Finally, for inpatients, information about the patient survival until day 30 will be collected from the patient’s file or hospital electronic data recording system.

At the end of the study period each participating center will provide an “end of study reporting form”
containing the number of the surgical procedures performed under anesthetic care during the study period and the total number of screening failure patients.

Furthermore each participating center will provide a screening failure tracking form at the end of the study period. Using this form it will be possible to analyze what were the reasons for exclusion from study (e.g. parents refused to sign informed consent if applicable, changes in the operation list, last minute cancellation, etc.).

4.4 Description of the measures taken to minimize/ avoid bias

The PEACH in Asia study is descriptive by nature and only includes objective data collected as part of routine care. In order to avoid a potential bias, all patients younger than 16 need to be included in each participating center. The patient’s clinical care will not be modified by study participation (observational study). All data will be anonymized and collected on a secure website: therefore there is high probability that written parental approval to participate will be waived by the local IRB (see the following ethics section).

In order to ensure adequacy and accuracy of data collection, national and local co-ordinators will be appointed with the following responsibilities:

National co-ordinators:

National co-ordinators will be appointed by the Steering Committee to lead the project within individual nations and:

- Identify local co-ordinators in participating centers
- Assist with translation of study paperwork as required
- Ensure necessary country or regional regulatory approvals are in place prior to the start date
- Ensure good communication with the participating sites in his/her nation

Local co-ordinators:

Local co-ordinators in individual institutions will:

- Provide leadership for the study in their institution
- Ensure all relevant regulatory approvals are in place for their institution
- Ensure adequate training of all relevant staff prior to data collection
- Supervise daily data collection and assist with problem solving
- Act as guarantor for the integrity and quality of data collected

All rights reserved. No reuse allowed without permission.
4.5 Expected duration of subject participation and description of the sequence and duration of study periods

Each patient included into the PEACH in Asia study will be followed up during the anesthesia management and up to 60 minutes afterwards. Furthermore, patients will be followed up to 30 days or until discharge following the occurrence of one of the severe critical events. Thus, initial data acquisition will be initiated at the day of the anesthesia management and a second set of data regarding survival parameters will be collected afterwards for inpatients.

4.6 “Stopping rules” or “discontinuation criteria” for individual subjects, parts of study and entire study

Apart from withdrawal of consent, no specific “stopping rules” or “discontinuation criteria” exist.

4.7 Pilot Testing

4.7.1 Purpose

A pilot study may be conducted prior to launching the main trial. This should test, on a small scale, all the study procedures, including the selection of eligible potential participants, their enrolment, recording the required data, supervision systems, quality control, and data processing.

4.7.2 Design of the pilot study

The design of the pilot study will be as similar as possible to the design of the procedures in the main trial, and the population selected to take part should be representative of the trial population (though not part of it). The pilot study will be conducted in a cluster which will not be included in the main trial, in order to avoid having to go back to the same individuals to collect similar data in the main trial.
Every step in the main trial processes will be tested in the pilot study. The pilot test of data must allow enough time for the pilot data to be entered on to computers, ‘cleaned’, and analyzed, so that these systems can also be checked for functionality.

The part of result(s) derived from the pilot study may be published as “feasibility and pilot study of the PEACH in Asia study,” though the data will not be used to calculate the sample size of the main trial, because generally speaking, a pilot study is not be designed with sufficient numbers or duration to give a precise enough estimate of main trial outcomes. Given very wide confidence intervals around the outcome estimates which are likely in a small pilot test, such projections may be very misleading.
5. Selection and Withdrawal of Subjects

5.1 Subject Inclusion/Exclusion Criteria

Eligibility Criteria:

Ages Eligible for Study: up to 15 Years (Child)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Sampling Method: Non-Probability Sample

Study Population:

All children aged less than 16 years old who are scheduled for an elective, urgent or emergency diagnostic or surgical procedure under sedation or general anesthesia with or without regional analgesia

Criteria:

Inclusion Criteria:
 ✓ Age: from birth to 15 years included
 ✓ All children admitted for an inpatient or outpatient procedure under general anesthesia with or without regional analgesia or under regional anesthesia alone. This includes all kind of surgeries and procedures requiring anesthesia and analgesia to be performed such as central venous access, burn care, cast, etc.
 ✓ Children admitted for a diagnostic procedure under sedation (performed by an anesthesiologist) or general anesthesia (such as endoscopy, radiology (CT-scan, MRI), cardiac catheterization and electrophysiology, PET-scan, radiotherapy, lumbar and bone marrow puncture, biopsies), diagnostic procedure under general anesthesia (such as endoscopy, radiology)
 ✓ Children admitted for urgent or emergency procedure performed in- or out-of-hours

Exclusion Criteria:
 × Children admitted directly from the intensive care units to the operating rooms
 × Anesthesia procedures in the neonatal or pediatric intensive care units
 × Age: All children aged ≥ 16 years
5.2 Subject Withdrawal Criteria

Apart from withdrawal of consent subjects will not be withdrawn from the study.

In case of withdrawal of consent, data collection will be stopped and the case report form (CRF) and the electronic case report form (e-CRF) of this patient will be left empty.

In case of withdrawal of consent, subjects will not be replaced.
Subjects that have withdrawn consent will not be followed-up.
6. Statistics

6.1 Sample size

On the basis of the European APRICOT (the rate of severe critical events: mean 5.2% [95% confidence interval (CI) 5.0-5.5] and considering the occurrence of the severe critical events studied in several Asian countries (all are single-center study: 3.3% in Singapore, 8.9% in India, and so on), we anticipate that a minimum of approximately 7,600 patients would provide a 95% CI of 1.0% for the overall incidence of severe critical events with an acceptable confidence width (assuming that the incidence of severe critical events is 5.2% with 95% CI of 4.7-5.7%). If we were able to recruit more patients as over 30,000, we could anticipate narrower CI such as 0.5%, assuming that the incidence of severe critical events is 5.2% with 95% CI of 5.0-5.5% as the European APRICOT. Thus, we plan to recruit at least 7,600 children over a period of two consecutive weeks including weekends and after-hours across the 15 Asian countries and regions represented at the Asian Society of Pediatric Anesthesiologists Council or part of geographical Asia. The 2-week recruitment period will be chosen by each site commencing on 01 April 2023 (as planned). The last possible inclusion date will be decided by the Study Steering Committee depending on the recruitment rate. Participating institutions will be provided with data acquisition sheets that enable anonymous standardized recording of all patients' parameters, which will be used by the local institution to fill in the electronic case report form (e-CRF).

Descriptive statistical analysis will be performed for the primary endpoint (occurrence of severe critical events and 95% confidence interval). Univariate and multivariate analysis will be performed to test factors associated with the endpoint. Results of logistic regression will be reported as adjusted odds ratio (OR) with 95% confidence intervals.

6.2 Participating centers

The PEACH in Asia study will recruit as many participating institutions as possible across the Asian countries or regions represented at the ASPA council and physical Asia. The recruitment will take place over a period of two consecutive weeks including weekends and after-hours. The 2-week recruitment period will be chosen by each site to occur in the course of 2023 and not later than March 31st 2024. Moreover, any Asian center is welcome to participate in this project, whether it is a private or public, academic, regional or referral center.
Protocol of PEACH in Asia study (English version)
November 3rd, 2022 (by the principal investigator, Sochiro Ohara, Japan)

Before inclusion of the first patient each institution will fill in a pre-study questionnaire regarding type and size of the hospital as well as some parameters regarding local standard of care. Each center will have a local coordinator and a national coordinator will be in contact with the participating centers in his/her country to ensure all is clarified (to answer possible questions) and follow recruitment. For detailed on responsibilities please refer to the section above.

6.3 Method

The PEACH in Asia study is a descriptive study; descriptive statistical methods will be used for the primary endpoint: the occurrence and 95% confidence interval will be given.

The data to be collected during the actual patient study are all part of routine clinical care. Categorial variables will be described as proportions and will be compared using chi-square or Fisher’s exact test. Continuous variables will be described as mean and standard deviation if normally distributed or median and inter-quartile range if not normally distributed. Comparisons of continuous variables will be performed using one-way ANOVA or Mann-Whitney test as appropriate. Univariate and multivariate analysis will be performed to test factors associated with the endpoints. A multiple hierarchical logistic or relative risk regression models will be used to identify independent risk factors. The choice of the variables in multivariate models will be based on p-values of the univariate tests (p<0.05) and on medical considerations.

Multicollinearity will be tested and will be taken into account. Stepwise elimination process will be used, along with medically plausible interactions. Results will be reported as adjusted odds ratio or relative risk with 95% confidence intervals. A single final analysis is planned at the end of the study. Since the PEACH in Asia study is a descriptive trial, and no changes of routine care are associated with the study no interim analysis is planned.

6.4 The level of significance to be used

A significance level of p<0.05 will be used for all statistical analyses.

6.5 Criteria for the termination of the study
Since no intervention will be performed, there are no criteria for termination of the trial.

6.6 Procedures for accounting for missing, unused, and spurious data

All patients will enter data analysis, regardless whether all data of the e-CRF has been surveyed. Unused and spurious data will be excluded from data analysis as soon as it is recognized.

6.7 The selection of subjects to be included in the analyses

All subjects that are included in the study will be included in the data analyses.
7. Quality Assurance and Quality Control

The sponsor, A-PEAR, is responsible for implementing and maintaining quality assurance and quality control systems to ensure that trials are conducted and data are generated, documented, and reported in compliance with the protocol, GCP standards, and the applicable regulatory requirements.

The sponsor, A-PEAR, is responsible for securing agreement from all involved parties to ensure direct access to all trial related sites, source data/documents and reports for the purpose of monitoring and auditing by the sponsor, and inspection by domestic and foreign regulatory authorities.

Quality control will be applied to each stage of data handling to ensure that all data are reliable and have been processed correctly.

Agreements, made by the sponsor, A-PEAR, with the principal investigator (Soichiro Obara), should be in writing, as part of the protocol or in a separate agreement.

The Sponsor, A-PEAR, has not put in place any form of contract or agreement with participating center to cover the clinical medical practices or activities they will undertake for the study. This is a very low risk data collection study and no harm will arise to patients as no aspect of their normal clinical medical care is being affected.

Any issues with the treatment they receive within the hospital they attend will be covered by local indemnity.
8. Ethics Description of Ethical Considerations Relating To The Study

The proposed study is an observational study with no interference with the child’s routine care, which is in accordance to the good clinical practice and no research-related interventions, will be introduced. Therefore, no ethical concerns are expected and ethical approval may not be required in some participating centers. However, where ethical approval is required, this approval must be obtained before the start of inclusion.

In all cases, all participating centers must submit the study to the local Institutional Review Board (IRB) for ethical judgment and obtain document of proof that the trial has been subject to IRB review and given approval/ favorable opinion and/ or waive the consent. If informed consent is not required by the local IRB, a written waiver must be obtained from the IRB. This process should take place prior to initiation of the trial and in compliance with the applicable national regulatory requirement(s).

If applicable, informed consent forms and any other written information to be provided to the parents/guardians as well as advertisement for subject recruitment (if used) should be subject to IRB review and given approval/ favorable opinion. The consent form will be obtained as it follows.

- Elective cases: The parents/guardians will be presented with Patient Information Sheet during the preoperative consultation or on the ward prior to anesthesia management and individual written consent will be sought during the consultation or in the holding bay or anesthetic room immediately prior to anesthesia.

- Children having emergency procedures: study data will be recorded and retrospective consent will be sought afterwards (and up to 48 hours following admission).

- Parents with longstanding incapacity to consent: (for example due to learning difficulties): Where time permits then a consultee should be approached (next of kin or consultant providing care) to request their assent. Where there isn’t time to approach a consultee prior to anesthesia then retrospective consent should be sought.

The study sponsor provides a template of Patient Information Sheet (case report form: CRF) and Participant’s Informed Consent and Authorized Informed Consent in English. All translation and adaptation of the participant’s informed consent and authorized informed consent form should be sent to the Sponsor, A-PEAR. Guidance published by the Sponsor should be followed.
Protocol of PEACH in Asia study (English version)
November 3rd, 2022 (by the principal investigator, Sochiro Obara, Japan)

9. Data Handling and Record Keeping

Participating local centers will be provided with data acquisition sheets (paper-case report forms: p-CRFs) that enable standardized recording of all patient’s parameters required for the study, and a combinable anonymization correspondence table for combining unanonymized Study Subject ID and the anonymized patient identification number at each participating local center.

Each local centers will be provided “3 digit code for the country” and “3 digit code for the hospital” by the sponsor of the study.

For data acquisition, each local centers (each local co-ordinator) issue the patient identification number (PIN) in order (3 digit individual patient number from 001 to 999). Each local co-ordinator keep the correspondence information (i.e. 3-digit individual patient number on the study and the patient identification number at each center) on the correspondence table provided by the study sponsor.

That is, study subject ID should be xxx(3 digit code for the country) – xxx(3 digit code for the participating hospital) – xxx(3 digit individual patient number) as the format.

The details of the anonymization process, parameters used and controls should be clearly recorded for future reference. Such documentation facilitates review, maintenance, fine-tuning and audits. Note that such documentation should be kept securely, as the release of the parameters may facilitate re-identification and disclosure of the anonymized data.

This correspondence table should be stored behind a lock by each local co-ordinator at each local participating center: the document must not be handed in to the national co-ordinators or the sponsor of this research (i.e. the A-PEAR group).

Thereafter the data are collected in an anonymous fashion. No patient names, patient initials or hospital patient identification numbers are kept on the paper case report form (p-CRF) or collected electronically on the electronic case report form (e-CRF).

Data will be handled confidentially and each local centers should keep all data stored for the length of the study and the time foreseen by local rules, but at least for a period of 5 years from the moment of the study completion. Each center will maintain an Investigator file including: protocol, IRB judgment, local investigator delegation log, local translation of informed consent form (if applicable), signed informed consent forms (if applicable), and so on.
Protocol of PEACH in Asia study (English version)
November 3rd, 2022 (by the principal investigator, Sochiro Ohara, Japan)

All handling of personal data will comply with the Good Clinical Practice Guidelines. All collected data will remain the property of the Sponsor, A-PEAR.
10. Publication Policy

After submitting grant proposal, recruitment of patients, data acquisition, cleaning and analysis of the data obtained, authorship will be distributed according to differences in investment.

Each participating center including at least 5 patients can designate one collaborator that will be mentioned in the publication. Furthermore, for each additional 50 patients included, one more collaborator can be designated. These collaborators will be mentioned in the manuscript and will be traceable via Pubmed.

Also, on request, participating centers will be allowed to use their data. Proposals for secondary analyses can be submitted to the Steering Committee, A-PEAR, that will need to approve those analyses and that will revise all papers originating from final analysis prior to submission.

Furthermore, the Sponsor of the study, A-PEAR and the Asian Society of Paediatric Anaesthesiologists, can use anonymized data for internal analyses and educational purposes.
11. References


13. Wan S, Siow YN, Lee SM, Ng A. Audits and critical incident reporting in paediatric anaesthesia:
Protocol of PEACH in Asia study (English version)
November 3rd, 2022 (by the principal investigator, Sochiro Obara, Japan)

12. Lists of Appendices

The lists of appendices:

Appendix 1. Patient Information Sheet in PEACH in Asia study

Appendix 2. Infographics of PEACH in Asia study

Appendix 3. Informed Consent sheet for PEACH in Asia study
   (required only if applicable according to the local IRB)

Appendix 4. Participating Institution Data Record Form in PEACH in Asia study

Appendix 5. Critical Events Definitions in PEACH in Asia study

Appendix 6. paper Case Report Form (p-CRF) in PEACH in Asia study

Appendix 7. Correspondence Table form for PEACH in Asia study
   (linking Study ID and Patients’ ID at the participating institution)

Appendix 8. Notification of the IRB review for PEACH in Asia study, obtained in Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan (as an international collaborative, multicenter observational study)